IM Cannabis (US:IMCC) Prnewswireยท2025-09-16 10:07Board Changes - IM Cannabis Corp. announced the resignation of Messrs. Shmulik Arbel and Brian Schinderle from the Board, Audit Committee, and Compensation Committee effective September 15, 2025 [1][2] - Messrs. Asaf Yitzhaik and Eli Zamir have been appointed to the Board and the Audit Committee to fill the vacancies created by the resignations, with Mr. Zamir also joining the Compensation Committee [2] New Board Members - Mr. Yitzhaik has over three decades of experience in retail and real estate, owning ASI Glasses and holding directorships in several publicly traded companies [3] - Mr. Zamir has extensive expertise in finance and capital markets, having served as CEO of an underwriting firm and CFO of a public real estate company, and currently leads M&A and financing activities in the renewable energy sector [4] Leadership Changes - Mr. Oz Adler has been appointed as the new Chairman of the Board, replacing Mr. Oren Shuster, who remains the Chief Executive Officer and a director [5] Strategic Review - The Company is conducting an ongoing strategic review and is exploring the introduction of additional business activities to enhance long-term growth opportunities and create further shareholder value [6] Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on sustainable and profitable growth in these high-value markets [7] - The Company operates a transnational ecosystem that includes importing and distributing cannabis, retail pharmacies, online platforms, and logistical hubs in Israel, as well as distributing cannabis to pharmacies in Germany through Adjupharm GmbH [8]